What happens after 2 doses of the Wegovy pen?

What the titration schedule tells us about the first two weeks

The licensed Wegovy schedule begins at 0.25 mg once weekly and stays there for approximately four weeks before the prescriber moves a patient up to 0.5 mg. Two doses in, you have completed roughly half that starter phase. The purpose of this gradual escalation is well-documented in the NICE technology appraisal for semaglutide (TA875): slower titration reduces the frequency and severity of gastrointestinal side effects that might otherwise lead people to stop treatment prematurely.

At 0.25 mg the medicine is present in your system but is not yet at the doses used in the main clinical trials. The STEP 1 trial (the pivotal study that underpins Wegovy's licence) tested semaglutide at the 2.4 mg maintenance dose over 68 weeks and found an average body-weight reduction of around 15%. That figure belongs to a much later stage of treatment. After two doses, you are nowhere near it, and that is completely normal.

This is also the phase where people often feel most uncertain. If you are reading this wondering whether something has gone wrong, or whether the treatment is working at all, that reaction is understandable, and our guide to what to expect from your Wegovy pen after 1 dose may help put those early feelings in context. The answer is almost certainly that nothing has gone wrong; the schedule is simply doing what it was designed to do.

Side effects that are common at this point, and ones that need prompt attention

Nausea is the side effect most often reported in the early weeks of Wegovy treatment, followed by looser stools, constipation, indigestion, burping and fatigue. These are well-recognised from the NHS medicines information for semaglutide and tend to be mild-to-moderate when they occur at the 0.25 mg dose. Eating smaller portions, avoiding high-fat meals around injection time, and staying well hydrated are measures the NHS and Wegovy's Patient Information Leaflet both suggest for managing this.

Most people find these symptoms settle within days to a couple of weeks. After two doses there is a reasonable chance you are already past the worst of them, or approaching that point.

A small number of side effects require medical attention promptly. Severe stomach pain that radiates to the back, with or without vomiting, should be assessed urgently because it can be a sign of pancreatitis, a rare but serious condition. The MHRA highlighted acute pancreatitis as a known risk of GLP-1 medicines in a Drug Safety Update issued in January 2026. Persistent vomiting that stops you keeping fluids down, signs of an allergic reaction, or any symptom that worries you significantly should also prompt a call to your GP or 111, not a wait until your next scheduled review. For reporting any suspected reaction, the MHRA Yellow Card scheme is available to patients directly.

What early appetite changes (or the absence of them) actually mean

Some people notice a perceptible reduction in appetite after just one or two injections; others notice very little at this stage. Both experiences are common and neither predicts how you will respond once you reach the maintenance dose. Semaglutide works partly by slowing gastric emptying and partly by acting on GLP-1 receptors in the brain that regulate satiety signals. These effects strengthen as the dose increases over the titration period, which can span several months before 2.4 mg is reached.

Weight loss at two doses is rarely substantial. A small reduction is possible, mainly if reduced appetite has already led to lower calorie intake, but the larger changes recorded in the STEP 1 trial accumulated over many months. If you are curious about what typically changes after four doses, that page covers the move from the starter phase into the first dose increase, and you may also find it useful to read about how the pen typically behaves after 3 doses as a stepping stone to get there.

It is also worth knowing that the titration timeline is set by clinical guidance, not by the scale of your early response. Whether your appetite is noticeably different or barely changed at week two, your prescriber will usually follow the same four-week schedule before considering a move upward, unless side effects make an early adjustment necessary.

Staying on track: practical considerations at this early stage

Consistency matters more at this point than results. Injecting on the same day each week, rotating sites between the abdomen, thigh and upper arm, and storing your pen correctly in the fridge at 2–8°C are all worth establishing as habits now, and if you want a closer look at how the pen performs in these opening weeks, our page on the Wegovy pen after one dose walks through what that first injection experience involves. The full breakdown of the Wegovy dose steps explains the schedule from start to maintenance and may help you see where you are heading.

Diet and activity still matter alongside the medicine. Wegovy is licensed for use with a reduced-calorie diet and increased physical activity; the treatment works with those changes, not instead of them. Your prescriber or dietitian is better placed than any general guide to advise what that looks like for you personally.

If you obtained Wegovy through a private clinic, you should have a clear way to contact your prescriber with concerns between scheduled reviews. At nume, aftercare is available seven days a week and every repeat order is clinically re-reviewed. For an overview of how the service works, our about page sets out what is included. If you have broader questions about Wegovy or are weighing up your options, our Wegovy treatment information page is a good place to continue. And if you are ready to talk through where you are in treatment, you are welcome to speak to our prescribers, no need to wait for your next scheduled check-in.